Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score-based weighting-Reference-Cited by-同舟云学术

Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score-based weighting

Published:2015-03 Issue:3 Volume:16 Page:143-151
ISSN:1751-2972
Container-title:Journal of Digestive Diseases
language:en
Short-container-title:Journal of Digestive Diseases

Author:

Kondo Masaaki¹,Morimoto Manabu¹²,Ishii Tomohiro¹,Nozaki Akito¹,Fukuda Hiroyuki¹,Numata Kazushi¹,Kobayashi Satoshi²,Ohkawa Shinichi²,Hidaka Hisashi³,Nakazawa Takahide³,Shibuya Akitaka³,Okuse Chiaki⁴,Suzuki Michihiro⁴,Sakamaki Kentaro⁵⁶,Morita Satoshi⁵⁶,Maeda Shin⁷,Tanaka Katsuaki¹⁶

Affiliation:

1. Gastroenterological Center; Yokohama City University Medical Center; Yokohama Japan

2. Hepatobiliary and Pancreatic Medical Oncology; Kanagawa Cancer Center Hospital; Yokohama Japan

3. Gastroenterology Division of Internal Medicine; Kitasato University East Hospital; Sagamihara Japan

4. Division of Gastroenterology and Hepatology; Department of Internal Medicine; St Marianna University School of Medicine; Kawasaki Japan

5. Departments of Biostatistics and Epidemiology; Yokohama City University Graduate School of Medicine; Yokohama Japan

6. Clinical Research Coordinating Center; Yokohama City University Medical Center; Yokohama Japan

7. Gastroenterology; Yokohama City University Graduate School of Medicine; Yokohama Japan

Publisher

Wiley

Subject

Gastroenterology

Reference24 articles.

1. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics;Shariff;Expert Rev Gastroenterol Hepatol,2009

2. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre;Grieco;Gut,2005

3. Design and endpoints of clinical trials in hepatocellular carcinoma;Llovet;J Natl Cancer Inst,2008

4. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res,2004

5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PCL/PRF/5;Liu;Cancer Res,2006

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors;Cancers;2022-01-31

2. A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma;Translational Cancer Research;2022-01

3. Progress in the Treatment of Hepatocellular Carcinoma Based on Hepatic Arterial Infusion Chemotherapy;Advances in Clinical Medicine;2022

4. The safety and efficacy of transarterial chemoembolisation with bleomycin for hepatocellular carcinoma unresponsive to doxorubicin: a prospective single-centre study;Clinical Radiology;2021-11

5. Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy;Journal of Clinical Medicine;2021-02-07